Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more
CMS appointed Brad Smith as director of the Center for Medicare & Medicaid Innovation, through which HHS plans to implement the Trump administration’s proposed International Pricing Index model for Medicare Part B drugs. Smith, who was COO of the diversified business group of Anthem Inc. (NYSE:ANTM), will also serve as senior adviser to HHS Secretary Alex Azar for value-based transformation (see “Trump Administration Signals IPI, Importation Rules are Advancing”).
FibroGen Inc. (NASDAQ:FGEN) hired Enrique Conterno as CEO. Conterno is a veteran of Eli Lilly and Co. (NYSE:LLY), where he served as president of Lilly USA, president of Lilly Diabetes and a member of the pharma’s corporate executive committee. Jim Schoeneck, who has served as interim CEO since the passing of Tom Neff, becomes chairman (see “FibroGen’s Neff Passes Away”)...